Genmab’s DuoBody™ Technology Gains Validation with Novartis Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 6 (Table of Contents)
Published: 15 Jun-2012
DOI: 10.3833/pdr.v2012.i6.1753 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Genmab has formed a bispecific antibody collaboration with Novartis that is potentially worth up to US$175 M plus research funding and royalties...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS